Comprehensive review of the repositioning of non-oncologic drugs for cancer immunotherapy-Reference-Cited by-同舟云学术

Comprehensive review of the repositioning of non-oncologic drugs for cancer immunotherapy

Published:2024-04-23 Issue:5 Volume:41 Page:
ISSN:1559-131X
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Rauf Abdur,Joshi Payal B.,Olatunde Ahmed,Hafeez Nabia,Ahmad Zubair,Hemeg Hassan A.,Aljohani Abdullah S. M.,Al Abdulmonem Waleed,Thiruvengadam Muthu,Viswanathan Dhivya,Rajakumar Govindasamy,Thiruvengadam Rekha

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12032-024-02368-8.pdf

Reference85 articles.

1. Olatunde A, Nigam M, Singh RK, Panwar AS, Lasisi A, Alhumaydhi FA, Jyoti kumar V, et al. Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs. Cancer Cell Int. 2021;21(1):499. https://doi.org/10.1186/s12935-021-02202-5.

2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

3. Fu L, Jin W, Zhang J, Zhu L, Lu J, Zhen Y, et al. Repurposing non-oncology small-molecule drugs to improve cancer therapy: current situation and future directions. Acta Pharm Sin B. 2022;12(2):532–57. https://doi.org/10.1016/j.apsb.2021.09.006.

4. Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med. 2017;177(11):1569–75. https://doi.org/10.1001/jamainternmed.2017.3601.

5. Kaushik I, Ramachandran S, Prasad S, Srivastava SK. Drug rechanneling: a novel paradigm for cancer treatment. Semin Cancer Biol. 2021;68:279–90. https://doi.org/10.1016/j.semcancer.2020.03.011.